<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938129</url>
  </required_header>
  <id_info>
    <org_study_id>201901749</org_study_id>
    <nct_id>NCT03938129</nct_id>
  </id_info>
  <brief_title>Improving Women's and Children's Health Via Biobanking and Electronic Registry</brief_title>
  <acronym>iELEVATE</acronym>
  <official_title>Improving Women's and Children's Health Via Biobanking and Electronic Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Santillan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnancy related diseases and exposures in pregnancy are known risk factors for future&#xD;
      disease. For example, women with a history of preeclampsia (a hypertensive disorder in&#xD;
      pregnancy) and children born to these women are at increased risk of cardiovascular disease&#xD;
      later in life. Yet, the mechanisms by which these long term health risks occur are unknown.&#xD;
      Clearly, this presents a significant public health hazard as preventative and therapeutic&#xD;
      interventions to block these pregnancy related diseases are limited. Current barriers to&#xD;
      studying these long-term mechanisms in existing cohorts include 1) lack of paired long-term&#xD;
      mother-child data, 2) lack of uniformly collected biosamples and 3) challenges in integrating&#xD;
      data from multiple sources and institutions. In particular, data and biosample collection&#xD;
      from rural and minority populations present significant challenges. The objective of the&#xD;
      iELEVATE proposal is to expand and diversify a current biobank to accelerate long-term&#xD;
      translational mechanistic and outcomes research in the vulnerable pregnancy population. We&#xD;
      will accomplish this by establishing a widely available biorepository that will collect a&#xD;
      first trimester blood and urine sample from pregnant women with a clinical data warehouse and&#xD;
      e-registry to support long-term prospective cohort studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1.Number of Participants and Controls Enrolled in Biobank [ Time Frame: 2 years ]</measure>
    <time_frame>2 years</time_frame>
    <description>Create bio-bank of maternal blood,urine and data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Maternal-Fetal Relations</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Pregnant women and their baby</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>1st trimester blood sample for bio-bank</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine sample</intervention_name>
    <description>1st trimester urine sample for bio-bank</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pregnancy, maternal health, and fetal health data</intervention_name>
    <description>Pregnancy, maternal health, and fetal health data</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1st trimester maternal blood and urine sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant woman in their first trimester.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pregnant women in their first trimester (less than 14 weeks) and have the capacity to&#xD;
        provide informed consent are eligible to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Under 18 years old, known non-viable pregnancy at time of consent,inability to provide&#xD;
        informed consent and diagnosis of a known infectious disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Santillan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB Gyn Associates, PC</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Group Obstetrics &amp; Gynecology Specialists, PC</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Des Moines OB GYN Associates, PC</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Institute</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>55401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Mark Santillan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

